[{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Melinta Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Rezafungin","moa":"Candida","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Melinta Therapeutics \/ Melinta Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Melinta Therapeutics \/ Melinta Therapeutics"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Rezafungin","moa":"Candida","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Melinta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Melinta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Rezafungin","moa":"Candida","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Melinta Therapeutics \/ Melinta Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Melinta Therapeutics \/ Melinta Therapeutics"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Rezafungin","moa":"Candida","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Melinta Therapeutics","amount2":0.46000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.46000000000000002,"dosageForm":"Injection","sponsorNew":"Melinta Therapeutics \/ Melinta Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Melinta Therapeutics \/ Melinta Therapeutics"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Rezafungin","moa":"Candida","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Melinta Therapeutics \/ Melinta Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Melinta Therapeutics \/ Melinta Therapeutics"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Rezafungin","moa":"Candida","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Melinta Therapeutics \/ Melinta Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Melinta Therapeutics \/ Melinta Therapeutics"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"Rezafungin","moa":"Candida","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Melinta Therapeutics \/ Cidara Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Melinta Therapeutics \/ Cidara Therapeutics"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"CorMedix","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Melinta Therapeutics","amount2":0.33000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.33000000000000002,"dosageForm":"Injection","sponsorNew":"Melinta Therapeutics \/ CorMedix","highestDevelopmentStatusID":"15","companyTruncated":"Melinta Therapeutics \/ CorMedix"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"CorMedix","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Melinta Therapeutics","amount2":0.33000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.33000000000000002,"dosageForm":"Injection","sponsorNew":"Melinta Therapeutics \/ CorMedix","highestDevelopmentStatusID":"15","companyTruncated":"Melinta Therapeutics \/ CorMedix"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Solithromycin","moa":"antibiotics (Streptomyces strains)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Melinta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Melinta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Imperial College London","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Solithromycin","moa":"antibiotics (Streptomyces strains)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Melinta Therapeutics \/ Melinta Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Melinta Therapeutics \/ Melinta Therapeutics"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Solithromycin","moa":"antibiotics (Streptomyces strains)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Melinta Therapeutics \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"10","companyTruncated":"Melinta Therapeutics \/ Biomedical Advanced Research and Development Authority"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Department of Health and Human Services","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Solithromycin","moa":"antibiotics (Streptomyces strains)","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Melinta Therapeutics \/ Department of Health and Human Services","highestDevelopmentStatusID":"6","companyTruncated":"Melinta Therapeutics \/ Department of Health and Human Services"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Department of Health and Human Services","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Solithromycin","moa":"antibiotics (Streptomyces strains)","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Melinta Therapeutics \/ Department of Health and Human Services","highestDevelopmentStatusID":"6","companyTruncated":"Melinta Therapeutics \/ Department of Health and Human Services"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Solithromycin","moa":"antibiotics (Streptomyces strains)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Melinta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Melinta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2012","type":"Inapplicable","leadProduct":"Solithromycin","moa":"antibiotics (Streptomyces strains)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Melinta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Melinta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Solithromycin","moa":"antibiotics (Streptomyces strains)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Melinta Therapeutics \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"10","companyTruncated":"Melinta Therapeutics \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2012","type":"Inapplicable","leadProduct":"Solithromycin","moa":"antibiotics (Streptomyces strains)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Melinta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Melinta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Solithromycin","moa":"antibiotics (Streptomyces strains)","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Melinta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Melinta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Tetraphase Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Merger","leadProduct":"Eravacycline","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Melinta Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.059999999999999998,"dosageForm":"Injection","sponsorNew":"Melinta Therapeutics \/ Melinta Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Melinta Therapeutics \/ Melinta Therapeutics"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Universit\u00e4tsklinikum K\u00f6ln | Innovative Medicines Initiative","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Undisclosed","graph2":"Phase I","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Melinta Therapeutics \/ Universit\u00e4tsklinikum K\u00f6ln | Innovative Medicines Initiative","highestDevelopmentStatusID":"6","companyTruncated":"Melinta Therapeutics \/ Universit\u00e4tsklinikum K\u00f6ln | Innovative Medicines Initiative"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Universit\u00e4tsklinikum K\u00f6ln | Innovative Medicines Initiative","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Nephrology","graph2":"Phase I","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Melinta Therapeutics \/ Universit\u00e4tsklinikum K\u00f6ln | Innovative Medicines Initiative","highestDevelopmentStatusID":"6","companyTruncated":"Melinta Therapeutics \/ Universit\u00e4tsklinikum K\u00f6ln | Innovative Medicines Initiative"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Delafloxacin","moa":"Bacterial DNA gyrase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Melinta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Melinta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Delafloxacin","moa":"Bacterial DNA gyrase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Melinta Therapeutics \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"6","companyTruncated":"Melinta Therapeutics \/ Biomedical Advanced Research and Development Authority"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Delafloxacin","moa":"Bacterial DNA gyrase","graph1":"Dermatology","graph2":"Phase III","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Melinta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Melinta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Delafloxacin","moa":"Bacterial DNA gyrase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Melinta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Melinta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Delafloxacin","moa":"Bacterial DNA gyrase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Melinta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Melinta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Partnership","leadProduct":"Delafloxacin","moa":"Bacterial DNA gyrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Melinta Therapeutics","amount2":0.14000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.14000000000000001,"dosageForm":"Tablet","sponsorNew":"Melinta Therapeutics \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"Melinta Therapeutics \/ BARDA"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Xediton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Licensing Agreement","leadProduct":"Delafloxacin","moa":"Bacterial DNA gyrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Melinta Therapeutics \/ Xediton Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Melinta Therapeutics \/ Xediton Pharmaceuticals"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Delafloxacin","moa":"Bacterial DNA gyrase","graph1":"Dermatology","graph2":"Phase III","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Melinta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Melinta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Delafloxacin","moa":"Bacterial DNA gyrase","graph1":"Dermatology","graph2":"Phase III","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Melinta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Melinta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Delafloxacin","moa":"Bacterial DNA gyrase","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Melinta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Melinta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"VenatoRx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Licensing Agreement","leadProduct":"Cefepime","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Melinta Therapeutics \/ VenatoRx Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Melinta Therapeutics \/ VenatoRx Pharmaceuticals"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"VenatoRx Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Cefepime","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Melinta Therapeutics \/ Melinta Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Melinta Therapeutics \/ Melinta Therapeutics"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Department of Health and Human Services","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Meropenem","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Melinta Therapeutics \/ Department of Health and Human Services","highestDevelopmentStatusID":"15","companyTruncated":"Melinta Therapeutics \/ Department of Health and Human Services"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Licensing Agreement","leadProduct":"Meropenem","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Melinta Therapeutics \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Melinta Therapeutics \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Meropenem","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Melinta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Melinta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Meropenem","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Melinta Therapeutics \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"8","companyTruncated":"Melinta Therapeutics \/ Biomedical Advanced Research and Development Authority"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Meropenem","moa":"Bacterial penicillin-binding protein","graph1":"Undisclosed","graph2":"Phase I","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Melinta Therapeutics \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"6","companyTruncated":"Melinta Therapeutics \/ Biomedical Advanced Research and Development Authority"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"New American Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"Metoprolol Succinate","moa":"Beta-1 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Melinta Therapeutics \/ Melinta Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Melinta Therapeutics \/ Melinta Therapeutics"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Department of Health and Human Services","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Meropenem And Vaborbactam","moa":"Beta-lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Melinta Therapeutics \/ Department of Health and Human Services","highestDevelopmentStatusID":"10","companyTruncated":"Melinta Therapeutics \/ Department of Health and Human Services"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Department of Health and Human Services","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Meropenem And Vaborbactam","moa":"Beta-lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Melinta Therapeutics \/ Department of Health and Human Services","highestDevelopmentStatusID":"6","companyTruncated":"Melinta Therapeutics \/ Department of Health and Human Services"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Controlled Substance","year":"2015","type":"Inapplicable","leadProduct":"Midazolam","moa":"GABA-A receptor; anion channel","graph1":"Undisclosed","graph2":"Phase I","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Syrup","sponsorNew":"Melinta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Melinta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Oritavancin","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Melinta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Melinta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Oritavancin","moa":"Peptidoglycan","graph1":"Undisclosed","graph2":"Phase I","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Melinta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Melinta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Christchurch Clinical Studies Trust","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Oritavancin","moa":"Peptidoglycan","graph1":"Undisclosed","graph2":"Phase I","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Melinta Therapeutics \/ Christchurch Clinical Studies Trust","highestDevelopmentStatusID":"6","companyTruncated":"Melinta Therapeutics \/ Christchurch Clinical Studies Trust"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Oritavancin","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Melinta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Melinta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Oritavancin","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Melinta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Melinta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Oritavancin","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Melinta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Melinta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Oritavancin Diphosphate","moa":"Peptidoglycan","graph1":"Undisclosed","graph2":"Phase I","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Melinta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Melinta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Oritavancin Diphosphate","moa":"Peptidoglycan","graph1":"Undisclosed","graph2":"Phase I","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Melinta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Melinta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Oritavancin Diphosphate","moa":"Peptidoglycan","graph1":"Undisclosed","graph2":"Phase I","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Melinta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Melinta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Oritavancin Diphosphate","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Melinta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Melinta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Oritavancin Diphosphate","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Melinta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Melinta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Fernanda P Silveira","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Rezafungin","moa":"Candida","graph1":"Immunology","graph2":"Phase III","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Melinta Therapeutics \/ Fernanda P Silveira","highestDevelopmentStatusID":"10","companyTruncated":"Melinta Therapeutics \/ Fernanda P Silveira"}]
Find Clinical Drug Pipeline Developments & Deals by Melinta Therapeutics
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
